Multidisciplinary cutting-edge technologies accelerating target-based drug discovery

Yanting Li; Ruin Moaddel; Zhengjin Jiang; Xiaofei Chen

doi:10.1016/j.jpha.2026.101592

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2026 > Accepted Manu

Yanting Li, Ruin Moaddel, Zhengjin Jiang, Xiaofei Chen. Multidisciplinary cutting-edge technologies accelerating target-based drug discovery[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101592

Citation:

Yanting Li, Ruin Moaddel, Zhengjin Jiang, Xiaofei Chen. Multidisciplinary cutting-edge technologies accelerating target-based drug discovery[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101592

Citation:

PDF( 424 KB)

Multidisciplinary cutting-edge technologies accelerating target-based drug discovery

doi: 10.1016/j.jpha.2026.101592

Yanting Li¹,
Ruin Moaddel^{2
,
,},
Zhengjin Jiang^{3
,
,},
Xiaofei Chen^{4
,
,}

1. School of Pharmacy, Naval Medical University, Shanghai, 200433, China;
2. National Institute on Aging, National Institutes of Health, Baltimore, MD, USA;
3. School of Pharmacy, Jinan University, Guangzhou, 510632, China;
4. School of Pharmacy, Naval Medical University, Shanghai, 200433, China

Available Online: Feb. 28, 2026

Abstract

FullText(HTML)

References(17)

References

[1]	D.S. Hage, S. Sharmeen, B.K. Sajeeb, et al., Studies and Analysis of Drug-Target Interactions by Affinity Chromatography and Related Techniques: A Review, J. Pharm. Anal. (2025),101402.
[2]	G. De Soricellis, E. Calleri, S. Salerno, et al., Latest surface plasmon resonance advances for G protein-coupled receptors, J. Pharm. Anal. (2025), 101381.
[3]	Y. Li, Y. Gu, W. Zhang, et al., Comparative two-dimensional NKG2A/CD94 cell membrane chromatography system for targeted screening immune checkpoint inhibitors, J. Pharm. Anal. (2025),101259.
[4]	L. Chen, D. Ke, Z. Jiang, et al., Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer, J. Pharm. Anal. (2025), 101335.
[5]	P.C.O. de Oliveira, B.S. do Amaral, C.L. Cardoso, et al., Breaking the boundaries of affinity selection-mass spectrometry: From ligand screening to target-ligand interaction insights, J. Pharm. Anal. (2025), 101379.
[6]	G.-H. Zhu, Y.-N. Zhang, Y. Xiong, et al., Uncovering the covalent inhibitors of SARS-CoV-2 Mpro in Tibetan edible herb Rhodiola crenulata and their synergistic anti-Mpro mechanism, J. Pharm. Anal. (2025), 101224.
[7]	L. Shen, X. Du, Y. Yang, et al., Development of A Novel NanoBRET High-Throughput Drug Screening Assay for Human GnRH Receptor Using Sulfo-cyanine 5 Fluorophore, J. Pharm. Anal. (2025), 101532.
[8]	D. Wu, Q. Hu, Q. Wu, et al., Synergistic cell membrane-coated ECL-DNA biosensor for specificity-enhanced drug lead evaluation, J. Pharm. Anal. (2025), 101515.
[9]	Y. Chang, H. Tian, J.-H. Qu, et al., Establishment of an at-line nanofractionation-based screening platform for rapid identification of influenza PAN/PAN I38T inhibitors from Artemisiae Argyi, J. Pharm. Anal. (2025), 101402.
[10]	H. Xu, M.A. Bittenbinder, J. Slagboom, et al., Profiling cytotoxicity of nanofractionated elapid snake venoms in human cell lines representing different tissues, J. Pharm. Anal. (2025), 101398.
[11]	J. Guo, Y. Song, M. Sun, et al., Discovery of anthraquinones as potent Notum inhibitors for treating osteoporosis by integrating biochemical, phytochemical, computational, and experimental assays, J. Pharm. Anal. (2025), 101256.
[12]	J. Gao, Y. Zheng, Y. Wang, et al., Oblique-incidence Reflectivity Difference Technology Identifies the Antiviral Drug Ribavirin as an Inhibitor of Lung Tumor Progression by Targeting AMPK Signaling, J. Pharm. Anal. (2025), 101306.
[13]	T. Tang, Y. Zhang, X. Xing, et al., Gliquidone alleviates DSS-induced ulcerative colitis in rats by targeting carnitine palmitoyltransferase 1A, J. Pharm. Anal. (2025), 101409.
[14]	Y. He, X. Tu, Y. Xue, et al., CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability, J. Pharm. Anal. (2025), 101357.
[15]	Y. Cui, Y. Chen, Y. Zhang, et al., Advances in aptamer technology for target-based drug discovery, J. Pharm. Anal. (2025), 101369.
[16]	Y. Zhou, Y. Zou, S. Lv, et al., Antibody screening for tumor and immune hotspot targets: the frontier of new methods and technologies, J. Pharm. Anal. (2025),101417.
[17]	R. Wang, Y. Yuan, H. Shao, et al., Real-Time Visualization of Drug-Target Interactions in Native Subcellular Microenvironments for Lysosome-targeted Drug Discovery, J. Pharm. Anal. (2025), 101428.